Compare Adaptive Biotechnologies Corp (ADPT) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs United States Natural Gas Fund — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while United States Natural Gas Fund trades at $11.58. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| ADPT | UNG | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Commodities - Energy |
52-Week High | $22.37 | $16.90 |
52-Week Low | $10.24 | $10.15 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
UNG trades at $11.71, up 1.12% today, with a bullish technical signal driven by moving averages. The fund tracks natural gas futures, with sentiment influenced by weather-driven demand and LNG export flows. Recent news highlights volatility from storage data and production forecasts, while technical indicators like RSI remain neutral.
Outlook hinges on natural gas price trends, with upside from demand spikes but risks from contango and ample supply. Investors face structural challenges, as noted in analysis citing decade-long losses, requiring caution despite short-term bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
